Why the label gets confusing
In everyday use, 'GLP-1' has become shorthand for the whole class of incretin medicines. Clinically, tirzepatide is a dual agonist – accurate to call it a GLP-1 receptor agonist, incomplete to stop there – the full side-by-side is here.
What GIP adds
GIP is the other major incretin hormone released after eating. Activating it alongside GLP-1 is the design difference behind tirzepatide, and the leading explanation for the larger average weight reduction seen in its obesity trials.
Does the distinction matter to you?
Practically, for insurance and clinical documentation, yes – the class matters. For daily experience, both are weekly injections with similar side-effect patterns and gradual titration.
Trial results belong to the specific FDA-approved product studied, at the doses studied.
What neither of them is
Not insulin, not a stimulant, not a steroid, and not a hormone-replacement therapy. Both are engineered peptides that amplify signals your gut already sends. See the 30-second film answers for this medication.
How tirzepatide works on two receptors at once
Tirzepatide is a single molecule that activates two incretin receptors: GIP and GLP-1. Both are receptors your gut already uses. After a meal, the intestine releases incretin hormones that tell the pancreas to release insulin, slow how fast the stomach empties, and signal fullness to the hypothalamus. Tirzepatide binds those same receptors, so the signal is present at a steadier level than it would be from food alone. The GLP-1 arm is the one most people have heard of. The GIP arm is what distinguishes tirzepatide from semaglutide, which acts on GLP-1 only. According to the FDA prescribing information for tirzepatide products, dual agonism is the mechanism of record. What that difference means for any individual is a clinical question, not a settled one, and a licensed clinician decides whether the medication is appropriate for you at all.
What compounded means, and what it does not
A compounded preparation is made by a licensed pharmacy for an individual patient on receipt of a valid prescription. Compounded drugs are not FDA-approved, and FDA does not review them for safety, effectiveness, or quality before they are marketed. That is a statement about regulatory pathway, not an accusation about any particular pharmacy, and it is why the distinction matters more than marketing language does. A compounded preparation is not a generic and not an equivalent of any FDA-approved brand product. Published clinical trials such as SURMOUNT-1 studied the branded product at studied doses; those findings should not be assumed to transfer. What compounded means unpacks the legal framework, and red flags when buying online covers how to tell a legitimate pharmacy from a grey-market seller.
A compounded preparation is not a generic of, or equivalent to, any FDA-approved product.
Why side effects are mostly digestive, and mostly early
Because the receptors tirzepatide acts on sit in the gut and the brainstem, the predictable effects are digestive: nausea, reflux, constipation, diarrhoea, and a feeling of fullness that arrives sooner than expected. According to FDA prescribing information for tirzepatide products, gastrointestinal reactions are the most commonly reported adverse events, and they are dose-related for many people. The practical implication is that they tend to cluster around a dose change rather than persist indefinitely. Serious risks are listed separately in the label, including pancreatitis, gallbladder disease, and a boxed warning for thyroid C-cell tumours in rodents. Those are not common, but they are the reason the medication is prescription-only. Report severe or persistent abdominal pain, vomiting that stops you keeping fluids down, or vision changes to your clinician promptly rather than waiting for a scheduled check-in.
What a titration schedule is actually for
Titration means starting at a dose below the one intended to be effective and stepping up on a schedule. It exists for tolerability, not caution for its own sake. Receptor signalling that arrives gradually gives the gut time to adapt, which is why the label sets minimum intervals between increases rather than leaving the pace open. Skipping ahead does not accelerate anything except side effects. Holding at a dose is a legitimate clinical decision, and so is stepping back down. If you want the lower end of that range as a deliberate plan rather than a waypoint, that is what microdosing describes. Your clinician sets the schedule, reviews how you are tolerating it, and adjusts. Nothing about a titration plan guarantees a particular result, and no schedule substitutes for the follow-up conversation that decides whether to continue.
About 10 minutes. Full refund if nothing is prescribed.
Frequently asked questions
So is tirzepatide stronger because it hits two receptors?
Trial averages favored tirzepatide on weight reduction. Mechanism plausibly explains it, but individual response still varies widely.
Is 'incretin medication' the better term?
It is the more precise umbrella term for both, yes.
Are there other dual or triple agonists?
Several are in development. Availability and evidence differ; only approved products are prescribed.
Is compounded tirzepatide the same as Zepbound?
No. Zepbound is an FDA-approved product; a compounded preparation is made by a licensed pharmacy for an individual patient and is not FDA-approved. FDA does not review compounded preparations for safety, effectiveness, or quality before marketing, and a compounded preparation is not a generic or an equivalent.
What is the starting dose of compounded tirzepatide?
Your prescribing clinician sets the starting dose and the titration schedule, and the dispensing pharmacy supplies instructions for your specific concentration. There is no single published starting dose for compounded preparations, and units and milligrams are not interchangeable.
How long can compounded tirzepatide be out of the fridge?
Follow the storage instructions supplied with your preparation, because the permitted excursion window depends on the exact formulation. If a package arrives warm, leaking, cloudy, or damaged, contact the dispensing pharmacy rather than using it.
Ask which class fits your history
A licensed clinician reviews your history and decides what is appropriate. Rx only, refunded in full if you are not prescribed.
Rx only. A licensed clinician decides whether treatment is appropriate and may determine that no treatment, or a different treatment, is right for you. Compounded medications are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality before marketing. Individual results vary.
Sources
Clinical trials listed below evaluated FDA-approved products at the doses studied. They are cited as published science, not as evidence about any compounded preparation, which is not FDA-approved and has not been evaluated by FDA for safety, effectiveness, or quality.
- Peer-reviewedCoskun T et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist. Mol Metab 2018;18:3-14
- Peer-reviewedFrías JP et al. Tirzepatide versus semaglutide once weekly (SURPASS-2). N Engl J Med 2021;385:503-515
- FDA databaseDrugs@FDA: search approved labeling for tirzepatide
- Peer-reviewedSURMOUNT-1: Tirzepatide Once Weekly for the Treatment of Obesity (NEJM 2022)
Spotted something inaccurate? Report an error – corrections are logged per our editorial standards.
More on Compare
Same medication, different question.
